文献速递胸部肿瘤放疗放疗物理与技术

早期非小细胞肺癌患者接受射波刀与基于直线加速器的容积旋转调强放疗立体定向体部放疗的比较研究

A Comparative Study of Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy Using CyberKnife and Linear Accelerator-Based Volumetric Modulated Arc Therapy.
PubMed 文献 · Pract Radiat Oncol · 2022-02-15

该研究纳入2012至2018年接受立体定向体部放疗的T1-2N0M0非小细胞肺癌患者227例(射波刀142例、容积旋转调强放疗85例),比较剂量学参数、肿瘤控制与临床结局。容积旋转调强放疗的局部、区域和远处控制及生存与射波刀相当,但区域控制更优(校正风险比0.26,P=0.045)。

要点

  • 227例早期非小细胞肺癌患者中,射波刀组142例、容积旋转调强放疗组85例。
  • 全组2年局部、区域和远处控制率分别为89.3%、86.3%和87.4%。
  • 容积旋转调强放疗与更优的区域控制相关(校正风险比0.26,P=0.045)。

核心结论

  • 容积旋转调强放疗与射波刀提供了相当的局部和远处控制及生存结局,但容积旋转调强放疗表现出更好的区域控制。
  • 原文结论指出在此方面进一步研究是必要的。

研究设计与样本

  • 比较研究,纳入2012至2018年接受立体定向体部放疗的T1-2N0M0非小细胞肺癌患者。
  • 共227例患者,其中射波刀组142例、容积旋转调强放疗组85例。
  • 收集靶区覆盖和危及器官剂量分布的剂量学参数。
  • 采用Kaplan-Meier法及对数秩检验评估生存结局。
  • 采用多因素Cox比例风险模型分析局部、区域和远处肿瘤控制、总生存和无进展生存以及放射性肺炎。

主要发现

  • 全组2年局部、区域和远处控制率分别为89.3%、86.3%和87.4%。
  • 全组2年和5年总生存率分别为67.5%和32.8%。
  • 容积旋转调强放疗给予大体肿瘤体积和计划靶区更高的最大剂量,且肺和心脏V5更低。
  • 局部失败、远处失败、无进展生存或总生存方面无差异,但容积旋转调强放疗与更优的区域失败自由相关(校正风险比0.26,P=0.045)。
  • 两种治疗方式间无差异,11.9%的患者发生1至2级放射性肺炎,无3级及以上放射性肺炎事件。

局限性

  • 原文结论指出在此方面进一步研究是必要的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy (SBRT) has become the standard of care for medically inoperable early-stage non-small cell lung cancer. We investigated 2 modalities of lung SBRT, CyberKnife (CK) and volumetric modulated arc therapy (VMAT), for differences in dosimetric parameters, tumor control, and clinical outcomes. METHODS AND MATERIALS: Patients who underwent SBRT for T1-2N0M0 non-small cell lung cancer from 2012 to 2018 were included. Dosimetric parameters for target volume coverage and organ-at-risk dose distribution were collected. Survival outcomes were evaluated using the Kaplan-Meier method with log-rank test. A multivariate Cox proportional hazards model was analyzed for local, regional, and distant tumor control; overall survival (OS) and progression-free survival; and radiation pneumonitis. RESULTS: Two hundred twenty-seven patients (142 CK, 85 VMAT SBRT) met inclusion criteria. Overall, the local, regional, and distant control rates were 89.3%, 86.3%, and 87.4% at 2 years, and the OS was 67.5% and 32.8% at 2 and 5 years, respectively. VMAT delivered higher maximum doses to the gross tumor volume and planning target volume and had a lower lung and heart V5. Although there was no difference in local or distant failure, progression-free survival, or OS, VMAT was associated with superior freedom from regional failure (adjusted hazard ratio, 0.26; P = .045). With no difference between treatment modalities, 11.9% of patients developed grade 1 to 2 radiation pneumonitis. There were no grade 3+ events of radiation pneumonitis. CONCLUSIONS: This study revealed that VMAT and CK provided comparable local and distant control and survival outcomes; however, VMAT exhibited better regional control. Further study in this regard is imperative.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Deshpande SR, Grubb WR, Kharouta M, et al. A Comparative Study of Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy Using CyberKnife and Linear Accelerator-Based Volumetric Modulated Arc Therapy. Pract Radiat Oncol. 2022. PMID: 35177369. doi:10.1016/j.prro.2021.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。